Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F

Rhea-AI Summary

Innate Pharma announced the filing of its 2021 Universal Registration Document with the French market authority AMF and its annual report on Form 20-F with the SEC. Both filings cover the year ending December 31, 2021, and are accessible via the company's and regulatory websites. Innate Pharma focuses on developing therapeutic antibodies for cancer treatment, supported by partnerships with major biopharmaceutical companies. The company is based in Marseille, France, and trades on Euronext Paris and Nasdaq under the ticker IPHA.

Positive

• Partnerships with major biopharmaceutical companies like Bristol-Myers Squibb and AstraZeneca enhance growth prospects.
• Filing of 2021 annual reports may indicate compliance and transparency, potentially fostering investor confidence.

Negative

• No financial metrics or results were disclosed in the filings, limiting visibility into financial performance.

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2021 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2021 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 4, 2022. It can be downloaded (in French) on the Company’s website and on the AMF’s website.

The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2021 with the United States Securities and Exchange Commission (“SEC”). It can be also be accessed on the Company’s website and on the SEC’s website.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com.

Information about Innate Pharma shares:

ISIN code Ticker code LEI

FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005556/en/

For additional information:

Investors and Media

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

ATCG Press

Marie Puvieux (France)

Tel.: +33 981 87 46 72

innate-pharma@atcg-partners.com

Source: Innate Pharma SA

FAQ

What is the purpose of Innate Pharma's 2021 Universal Registration Document?

The 2021 Universal Registration Document is a regulatory filing to provide detailed information about Innate Pharma's operations and financials for compliance with French market regulations.

When did Innate Pharma file its annual report on Form 20-F with the SEC?

Innate Pharma filed its annual report on Form 20-F with the SEC on April 4, 2022, covering the year ending December 31, 2021.

How can investors access Innate Pharma's annual report?

Investors can access Innate Pharma's annual report on Form 20-F through the company's website or the SEC's website.

What is Innate Pharma's focus in the biotech industry?

Innate Pharma is focused on developing therapeutic antibodies for oncology, aiming to improve cancer treatment and patient outcomes.

Where is Innate Pharma headquartered?

Innate Pharma is headquartered in Marseille, France, and has a U.S. office in Rockville, MD.